Envista Holdings Corp (NVST) Stock Competitors & Peer Comparison
See (NVST) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Equipment & Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NVST | $24.68 | +0.33% | 4B | 60.20 | $0.41 | N/A |
| SIRO | $109.97 | +0.00% | 22B | N/A | N/A | N/A |
| HIMS | $30.17 | +12.49% | 6.7B | -335.22 | -$0.09 | N/A |
| CON | $28.15 | +0.07% | 3.6B | 20.24 | $1.39 | +0.89% |
| BBNX | $14.38 | -1.03% | 640.8M | -10.50 | -$1.37 | N/A |
| CV | $7.23 | +0.56% | 361.2M | -6.82 | -$1.06 | N/A |
| KDLY | $11.30 | +1.16% | 68.1M | -15.48 | -$0.73 | N/A |
| NEUE | $6.75 | +0.00% | 60.9M | -0.38 | -$17.65 | N/A |
| PARK | $17.84 | -0.78% | 34.7M | -34.98 | -$0.51 | N/A |
| PFSA | $0.24 | +5.40% | 131.6K | -0.02 | -$15.36 | N/A |
Stock Comparison
NVST vs SIRO Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, SIRO has a market cap of 22B. Regarding current trading prices, NVST is priced at $24.68, while SIRO trades at $109.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas SIRO's P/E ratio is N/A. In terms of profitability, NVST's ROE is +0.02%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, NVST is more volatile compared to SIRO. This indicates potentially higher risk in terms of short-term price fluctuations for NVST.Check SIRO's competition here
NVST vs HIMS Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, HIMS has a market cap of 6.7B. Regarding current trading prices, NVST is priced at $24.68, while HIMS trades at $30.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas HIMS's P/E ratio is -335.22. In terms of profitability, NVST's ROE is +0.02%, compared to HIMS's ROE of -0.02%. Regarding short-term risk, NVST is less volatile compared to HIMS. This indicates potentially lower risk in terms of short-term price fluctuations for NVST.Check HIMS's competition here
NVST vs CON Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, CON has a market cap of 3.6B. Regarding current trading prices, NVST is priced at $24.68, while CON trades at $28.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas CON's P/E ratio is 20.24. In terms of profitability, NVST's ROE is +0.02%, compared to CON's ROE of +0.46%. Regarding short-term risk, NVST is more volatile compared to CON. This indicates potentially higher risk in terms of short-term price fluctuations for NVST.Check CON's competition here
NVST vs BBNX Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, BBNX has a market cap of 640.8M. Regarding current trading prices, NVST is priced at $24.68, while BBNX trades at $14.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas BBNX's P/E ratio is -10.50. In terms of profitability, NVST's ROE is +0.02%, compared to BBNX's ROE of -0.23%. Regarding short-term risk, NVST is less volatile compared to BBNX. This indicates potentially lower risk in terms of short-term price fluctuations for NVST.Check BBNX's competition here
NVST vs CV Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, CV has a market cap of 361.2M. Regarding current trading prices, NVST is priced at $24.68, while CV trades at $7.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas CV's P/E ratio is -6.82. In terms of profitability, NVST's ROE is +0.02%, compared to CV's ROE of +1.27%. Regarding short-term risk, NVST is less volatile compared to CV. This indicates potentially lower risk in terms of short-term price fluctuations for NVST.Check CV's competition here
NVST vs KDLY Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, NVST is priced at $24.68, while KDLY trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas KDLY's P/E ratio is -15.48. In terms of profitability, NVST's ROE is +0.02%, compared to KDLY's ROE of -0.85%. Regarding short-term risk, NVST is less volatile compared to KDLY. This indicates potentially lower risk in terms of short-term price fluctuations for NVST.Check KDLY's competition here
NVST vs NEUE Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, NVST is priced at $24.68, while NEUE trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas NEUE's P/E ratio is -0.38. In terms of profitability, NVST's ROE is +0.02%, compared to NEUE's ROE of +0.06%. Regarding short-term risk, NVST is more volatile compared to NEUE. This indicates potentially higher risk in terms of short-term price fluctuations for NVST.Check NEUE's competition here
NVST vs PARK Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, PARK has a market cap of 34.7M. Regarding current trading prices, NVST is priced at $24.68, while PARK trades at $17.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas PARK's P/E ratio is -34.98. In terms of profitability, NVST's ROE is +0.02%, compared to PARK's ROE of -0.24%. Regarding short-term risk, NVST is less volatile compared to PARK. This indicates potentially lower risk in terms of short-term price fluctuations for NVST.Check PARK's competition here
NVST vs PFSA Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, PFSA has a market cap of 131.6K. Regarding current trading prices, NVST is priced at $24.68, while PFSA trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas PFSA's P/E ratio is -0.02. In terms of profitability, NVST's ROE is +0.02%, compared to PFSA's ROE of +1.54%. Regarding short-term risk, NVST is less volatile compared to PFSA. This indicates potentially lower risk in terms of short-term price fluctuations for NVST.Check PFSA's competition here
NVST vs EVHC Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, EVHC has a market cap of 0. Regarding current trading prices, NVST is priced at $24.68, while EVHC trades at $45.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas EVHC's P/E ratio is N/A. In terms of profitability, NVST's ROE is +0.02%, compared to EVHC's ROE of +0.07%. Regarding short-term risk, NVST is more volatile compared to EVHC. This indicates potentially higher risk in terms of short-term price fluctuations for NVST.Check EVHC's competition here
NVST vs CYNO Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, CYNO has a market cap of 0. Regarding current trading prices, NVST is priced at $24.68, while CYNO trades at $66.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas CYNO's P/E ratio is N/A. In terms of profitability, NVST's ROE is +0.02%, compared to CYNO's ROE of +0.03%. Regarding short-term risk, NVST is more volatile compared to CYNO. This indicates potentially higher risk in terms of short-term price fluctuations for NVST.Check CYNO's competition here
NVST vs COTV Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, COTV has a market cap of 0. Regarding current trading prices, NVST is priced at $24.68, while COTV trades at $44.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas COTV's P/E ratio is N/A. In terms of profitability, NVST's ROE is +0.02%, compared to COTV's ROE of +0.14%. Regarding short-term risk, NVST is more volatile compared to COTV. This indicates potentially higher risk in terms of short-term price fluctuations for NVST.Check COTV's competition here
NVST vs AMSG Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, AMSG has a market cap of 0. Regarding current trading prices, NVST is priced at $24.68, while AMSG trades at $67.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas AMSG's P/E ratio is N/A. In terms of profitability, NVST's ROE is +0.02%, compared to AMSG's ROE of +0.08%. Regarding short-term risk, NVST is less volatile compared to AMSG. This indicates potentially lower risk in terms of short-term price fluctuations for NVST.Check AMSG's competition here
NVST vs SPAN Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, SPAN has a market cap of 0. Regarding current trading prices, NVST is priced at $24.68, while SPAN trades at $29.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas SPAN's P/E ratio is N/A. In terms of profitability, NVST's ROE is +0.02%, compared to SPAN's ROE of +0.17%. Regarding short-term risk, NVST is less volatile compared to SPAN. This indicates potentially lower risk in terms of short-term price fluctuations for NVST.Check SPAN's competition here
NVST vs SCAI Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, SCAI has a market cap of 0. Regarding current trading prices, NVST is priced at $24.68, while SCAI trades at $55.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas SCAI's P/E ratio is N/A. In terms of profitability, NVST's ROE is +0.02%, compared to SCAI's ROE of +0.09%. Regarding short-term risk, NVST is more volatile compared to SCAI. This indicates potentially higher risk in terms of short-term price fluctuations for NVST.Check SCAI's competition here
NVST vs DSCI Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, DSCI has a market cap of 0. Regarding current trading prices, NVST is priced at $24.68, while DSCI trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas DSCI's P/E ratio is N/A. In terms of profitability, NVST's ROE is +0.02%, compared to DSCI's ROE of -0.00%. Regarding short-term risk, NVST is more volatile compared to DSCI. This indicates potentially higher risk in terms of short-term price fluctuations for NVST.Check DSCI's competition here
NVST vs PMC Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, PMC has a market cap of 0. Regarding current trading prices, NVST is priced at $24.68, while PMC trades at $29.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas PMC's P/E ratio is N/A. In terms of profitability, NVST's ROE is +0.02%, compared to PMC's ROE of +0.04%. Regarding short-term risk, NVST is more volatile compared to PMC. This indicates potentially higher risk in terms of short-term price fluctuations for NVST.Check PMC's competition here
NVST vs SPNC Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, SPNC has a market cap of 0. Regarding current trading prices, NVST is priced at $24.68, while SPNC trades at $38.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas SPNC's P/E ratio is N/A. In terms of profitability, NVST's ROE is +0.02%, compared to SPNC's ROE of -0.61%. Regarding short-term risk, NVST is more volatile compared to SPNC. This indicates potentially higher risk in terms of short-term price fluctuations for NVST.Check SPNC's competition here
NVST vs MEDC Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, MEDC has a market cap of 0. Regarding current trading prices, NVST is priced at $24.68, while MEDC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas MEDC's P/E ratio is N/A. In terms of profitability, NVST's ROE is +0.02%, compared to MEDC's ROE of N/A. Regarding short-term risk, NVST is less volatile compared to MEDC. This indicates potentially lower risk in terms of short-term price fluctuations for NVST.Check MEDC's competition here
NVST vs ABAX Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, ABAX has a market cap of 0. Regarding current trading prices, NVST is priced at $24.68, while ABAX trades at $83.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas ABAX's P/E ratio is N/A. In terms of profitability, NVST's ROE is +0.02%, compared to ABAX's ROE of +0.10%. Regarding short-term risk, NVST is more volatile compared to ABAX. This indicates potentially higher risk in terms of short-term price fluctuations for NVST.Check ABAX's competition here
NVST vs ABCO Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, ABCO has a market cap of 0. Regarding current trading prices, NVST is priced at $24.68, while ABCO trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas ABCO's P/E ratio is N/A. In terms of profitability, NVST's ROE is +0.02%, compared to ABCO's ROE of +0.19%. Regarding short-term risk, NVST is more volatile compared to ABCO. This indicates potentially higher risk in terms of short-term price fluctuations for NVST.Check ABCO's competition here
NVST vs LPNT Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, LPNT has a market cap of 0. Regarding current trading prices, NVST is priced at $24.68, while LPNT trades at $64.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas LPNT's P/E ratio is N/A. In terms of profitability, NVST's ROE is +0.02%, compared to LPNT's ROE of +0.05%. Regarding short-term risk, NVST is more volatile compared to LPNT. This indicates potentially higher risk in terms of short-term price fluctuations for NVST.Check LPNT's competition here
NVST vs STJ Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, STJ has a market cap of 0. Regarding current trading prices, NVST is priced at $24.68, while STJ trades at $80.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas STJ's P/E ratio is N/A. In terms of profitability, NVST's ROE is +0.02%, compared to STJ's ROE of +0.21%. Regarding short-term risk, NVST is more volatile compared to STJ. This indicates potentially higher risk in terms of short-term price fluctuations for NVST.Check STJ's competition here
NVST vs MZOR Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, MZOR has a market cap of 0. Regarding current trading prices, NVST is priced at $24.68, while MZOR trades at $58.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas MZOR's P/E ratio is N/A. In terms of profitability, NVST's ROE is +0.02%, compared to MZOR's ROE of -0.14%. Regarding short-term risk, NVST is more volatile compared to MZOR. This indicates potentially higher risk in terms of short-term price fluctuations for NVST.Check MZOR's competition here
NVST vs EXAC Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, EXAC has a market cap of 0. Regarding current trading prices, NVST is priced at $24.68, while EXAC trades at $49.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas EXAC's P/E ratio is N/A. In terms of profitability, NVST's ROE is +0.02%, compared to EXAC's ROE of +0.00%. Regarding short-term risk, NVST is more volatile compared to EXAC. This indicates potentially higher risk in terms of short-term price fluctuations for NVST.Check EXAC's competition here
NVST vs LDR Comparison June 2026
NVST plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVST stands at 4B. In comparison, LDR has a market cap of 0. Regarding current trading prices, NVST is priced at $24.68, while LDR trades at $67.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVST currently has a P/E ratio of 60.20, whereas LDR's P/E ratio is N/A. In terms of profitability, NVST's ROE is +0.02%, compared to LDR's ROE of +1.17%. Regarding short-term risk, NVST is more volatile compared to LDR. This indicates potentially higher risk in terms of short-term price fluctuations for NVST.Check LDR's competition here